Literature DB >> 18359635

Synthesis and biological evaluation of thiobenzanilides as anticancer agents.

Wan-Ping Hu1, Hsin-Su Yu, Yan-Ren Chen, Yi-Min Tsai, Yin-Kai Chen, Chao-Cheng Liao, Long-Sen Chang, Jeh-Jeng Wang.   

Abstract

A series of novel thiobenzanilides is described. These compounds have been previously found to show strong biological activity such as antimycotic and antifungal actions. This is the first demonstration on the mechanism of the anticancer effect of thiobenzanilide agents (4a-c) on human melanoma A375 cells. The cytotoxic studies of compounds 4a-c on human melanoma A375 cells indicate thiobenzanilides induced higher cytotoxicity than nitrobenzanilides (3a-c). In addition, DNA flow cytometric analysis shows that 4a-c displays a significant G2/M phase arrest, which progresses to early apoptosis as detected by flow cytometry after double-staining with annexin V and propidium iodide (PI). Because cellular apoptosis is often preceded by the disruption of mitochondrial function, the assessment of mitochondrial function in 4a-c-treated cells is worthy of investigation. Our data revealed that treatment of A375 cells with 4a-c resulted in the loss of mitochondrial membrane potential (DeltaPsi(mt)), a reduction of ATP synthesis, increased reactive oxygen species (ROS) generation, and activation of caspase-3. Thus, we suggest that 4a-c agents are potent inducers of cell apoptosis in A375 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359635     DOI: 10.1016/j.bmc.2008.03.003

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.

Authors:  Raúl Ortiz; Jose Prados; Consolacion Melguizo; Ana R Rama; Ana Segura; Fernando Rodríguez-Serrano; Houria Boulaiz; Fidel Hita; Antonio Martinez-Amat; Roberto Madeddu; Juan L Ramos; Antonia Aranega
Journal:  J Mol Med (Berl)       Date:  2009-07-05       Impact factor: 4.599

2.  Novel ferrocenyl derivatives exert anti-cancer effect in human lung cancer cells in vitro via inducing G1-phase arrest and senescence.

Authors:  Ying Li; Han-lin Ma; Lei Han; Wei-yong Liu; Bao-xiang Zhao; Shang-li Zhang; Jun-ying Miao
Journal:  Acta Pharmacol Sin       Date:  2013-05-06       Impact factor: 6.150

3.  4-Bromo-N-phenyl-benzamide.

Authors:  Hoong-Kun Fun; Suchada Chantrapromma; Weerawat Sripet; Pumsak Ruanwas; Nawong Boonnak
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-03-31

4.  Cytotoxicity and Structure-activity Relationships of Naphthyridine Derivatives in Human Cervical Cancer, Leukemia, and Prostate Cancer.

Authors:  Yu Jin Hwang; Mi Lyang Chung; Uy Dong Sohn; Chaeuk Im
Journal:  Korean J Physiol Pharmacol       Date:  2013-12-16       Impact factor: 2.016

5.  2-(4-Fluorophenyl)-N-phenylacetamide Derivatives as Anticancer Agents: Synthesis and In-vitro Cytotoxicity Evaluation.

Authors:  Alireza Aliabadi; Sajad Andisheh; Zahra Tayarani-Najaran; Mona Tayarani-Najaran
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

6.  The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines.

Authors:  Malgorzata Kucinska; Helena Mieszczak; Hanna Piotrowska-Kempisty; Mariusz Kaczmarek; Walter Granig; Marek Murias; Thomas Erker
Journal:  Invest New Drugs       Date:  2018-11-29       Impact factor: 3.850

Review 7.  More Than Resveratrol: New Insights into Stilbene-Based Compounds.

Authors:  Paulina Pecyna; Joanna Wargula; Marek Murias; Malgorzata Kucinska
Journal:  Biomolecules       Date:  2020-07-27

8.  Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides.

Authors:  Malgorzata Kucinska; Maria-Dolores Giron; Hanna Piotrowska; Natalia Lisiak; Walter H Granig; Francisco-Javier Lopez-Jaramillo; Rafael Salto; Marek Murias; Thomas Erker
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.